Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

• Prif Awduron: Steven N. Austad (Awdur), Scott Ballinger (Awdur), Thomas W. Buford (Awdur), Christy S. Carter (Awdur), Daniel L. Smith, Jr (Awdur), Victor Darley-Usmar (Awdur), Jianhua Zhang (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Elsevier, 2022-02-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular m...